The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Yep that's right TVC, this is exactly the type of license agreement Avacta could be enjoying before too long:
"Under the terms of the agreement, Xilio granted Gilead an exclusive global license to develop and commercialize XTX301, Xilio’s tumor-activated IL-12. Xilio will receive $43.5 million in upfront payments, including a cash payment of $30.0 million and an initial equity investment by Gilead of $13.5 million in Xilio common stock at a premium. Xilio will be eligible to receive up to $604.0 million in additional contingent payments, including additional equity investments by Gilead, a transition fee and specified development, regulatory and sales-based milestones. Xilio will also be eligible to receive tiered royalties ranging from high single digits to mid-teens on annual global net product sales."
The counter argument is that now is a great time to buy low. Look at the last drop down to 38p a couple of years ago. Anyone brave enough to invest at that time enjoyed 4-5 times returns over a relatively short period. Is Avacta in a better or worse position than then? Clearly better.
The charts show the share price is in a descending wedge, which is a bullish indicator, and is usually accompanied by a strong reversal. This will likely come on the lead up to AACR, or even at that event when additional information is released on cohorts 6 and 7.
What I imagine might be useful is some kind of quick and easy diagnostic kit, where the detection of e.g. the leaving group or some other byproduct, could be used to infer activity in the tumour. Another possibility is some kind of radioactive tracer that could be used in conjunction with precision, effectively lighting up the tumour if fap is present.
Touk the delivery mechanism works, there’s no doubt about that. The complexity is navigating the pharmacokinetic landscape and understanding how and when this treatment is applicable ie. does the tumour exhibit sufficient active fap and can ava6000 be delivered to the tumour site in sufficient concentrations.
I'm fairly confident this will rise up at some point in the not too distant future. It's perfectly normal for investors to feel aggrieved in these circumstances and for it to seem like the sun will never come back up.
As for baying for AS's blood, my take is that he should remain and continue to build the team around him that has the commercial and clinical experience needed to get this over the finish line, which I happen to think is a process that is already underway.
it's also yet another example of "the market" being represented by a couple of thick as pig **** participants, when it comes to understanding the voracity of the underlying tech. do you hear that wyndrum, i don't want hear it from you again that the sp reflects where the trial or the tech is. two prime examples, so **** right off.
interviewing another bit of vermin. this time ph rambles on at the guy for about 5 minutes extolling the virtues of avacta and their wonderful teck and lamenting at how difficult it is to raise money at this time. guy just replies:
"yeah, no idea what you're talking about mate. but yeah of course companies have to raise money before they need it or the investors will take advantage and offer less and you'll need to accept it, huh huh. then you've got shorters, like me, who come in shorting the stock looking to cover in the placing"
yeah, you ****, you can do that because you've been tipped off that there's a placing coming in at x. there he is, that's what he looks like if you want to throw your tomatoes at him.
Indeed, and a quick search of paclitaxel, the example given by CC, shows that the dosing regimen changes depending on the condition, and in future I imagine AVA6000 will also be the same. That said, there are a million different dosing regimens that could be explored, so that is something that clinicians may experiment in future trials, and not necessarily something that would be adopted now. But who knows, the trial is evolving before our eyes!